Crossmark

Changes in the proportion of clinical clusters contribute to the phenotypic evolution of Behçet’s disease in Japan

Published Online: 2021-02-01

Published Print: 2021-12

Authors

Soejima, Yutaro

Kirino, Yohei https://orcid.org/0000-0002-9488-661X
Takeno, Mitsuhiro

Kurosawa, Michiko

Takeuchi, Masaki

Yoshimi, Ryusuke

Sugiyama, Yumiko

Ohno, Shigeru

Asami, Yukiko

Sekiguchi, Akiko

Igarashi, Toshihisa

Nagaoka, Shohei

Ishigatsubo, Yoshiaki

Nakajima, Hideaki

Mizuki, Nobuhisa
Funding

Funding for this research was provided by:

Ministry of Health, Labour and Welfare (19H03700, 17K09990)
License Information

Text and Data Mining valid from 2021-02-01

Version of Record valid from 2021-02-01
More Information

Article History

Received: 10 August 2020

Accepted: 25 December 2020

First Online: 1 February 2021

Ethics approval and consent to participate

: The study was approved by the Ethics Committee of YCU (A191100002). This survey is based on the application of the opt-out strategy in accordance with Japan MHLW Epidemiological Research Ethics Guidelines.

: Not applicable.

: Y. Kirino: Amgen (speaking and consultation fees); M. Takeno: Amgen (advisor for the clinical trial of Apremilast); and S. Nagaoka: Chugai, Bristol-Myers Squibb, Gilead (consultation fees).

Document is current